While the DMD gene, mRNA, and protein were ‘difficult tools’, two opportunities opened up that facilitated recent advances in therapies: Becker dystrophy and the ‘semifunctional’ dystrophins, and increasing knowledge of the progressive pathophysiology of DMD. This evidence concerns the gene DMD and Duchenne muscular dystrophy.